Lupin arm gets USFDA nod to market bacterial infection generic tablets

New Delhi: Drug major Lupin Wednesday said its subsidiary Gavis Pharmaceuticals has received approval from the US health regulator to market generic linezolid tablets used for treating bacterial infection in the American market.



The company's US-based subsidiary Gavis Pharmaceuticals has received final approval for its linezolid tablets in 600 mg strength from the US Food and Drug Administration (USFDA), Lupin said in a BSE filing.

Gavis' product is a generic version of Pharmacia and Upjohn company's Zyvox tablets, which is indicated in adults and children for treatment of certain infections caused by susceptible gram-positive bacteria.

As per IMS MAT June sales data, Zyvox tablets had US sales of $273.6 million.

The stock ended 2.20 percent down at Rs 1,520.50 on BSE.

Updated Date: Aug 24, 2016 16:36 PM

Also See